PharmiWeb.com - Global Pharma News & Resources
04-Feb-2019

Muscarinic M1 Agonist - Pipeline Insight, 2019 - ResearchAndMarkets.com

The "Muscarinic M1 Agonist -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Muscarinic M1 Agonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

  • Provides a snapshot of the therapeutics pipeline activity for Muscarinic M1 Agonist
  • Features the Muscarinic M1 Agonist pipeline across the complete product development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of Muscarinic M1 Agonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Muscarinic M1 Agonist

Reasons to Buy

  • Establish a comprehensive understanding of the current pipeline scenario across Muscarinic M1 Agonist to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Muscarinic M1 Agonist research & development (R&D)
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify and understand the sought after therapy areas and indications for Muscarinic M1 Agonist
  • Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Muscarinic M1 Agonist to enhance and expand business potential and scope
  • Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress

Companies Featured

  • Heptares Therapeutics
  • WinSanTor
  • Anavex Life Sciences
  • Mithridion
  • Boehringer Ingelheim
  • Glenmark Pharmaceuticals Ltd.

Topics Covered

1. Report Introduction

2. Muscarinic M1 Agonist - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Muscarinic M1 Agonist

4. Comparative Analysis

5. Muscarinic M1 Agonist Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Muscarinic M1 Agonist Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/htsh33/muscarinic_m1?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190204005680/en/

Editor Details

Last Updated: 04-Feb-2019